Alizyme plc (LSE:AZM) has successfully completed its pharmacokinetic/pharmacodynamic clinical trial of cetilistat in obese volunteers, under its Investigational New Drug (IND) application in the USA.

Key Messages

• Confirms excellent profile of cetilistat, with high levels of tolerability in American obese subjects similar to that previously seen in European clinical trials
• An important step forward for cetilistat in its development for the commercially significant USA market
• Provides further evidence of cetilistat’s competitive profile ahead of results of data from the 612 patient European Phase IIb trial in obese diabetics in December

Read more about Alizyme's clinical trials on a new weight loss drug at http://www.medadnews.com/News/Index.cfm?articleid=289244.